Beijing Konruns Pharmaceutical Co., Ltd. Class ASSE: 603590

Announcement on Completion of the First Subject Enrollment in the Phase 1 Clinical Trial of KC1086

· Issued by Beijing Konruns Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Completion of the First Subject Enrollment in the Phase 1 Clinical Trial of KC1086

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis